Discovery of Screening Biomarkers for Major Depressive Disorder in Remission by Proteomic Approach
نویسندگان
چکیده
منابع مشابه
Remission and functioning in major depressive disorder.
Evidence from numerous clinical studies has shown that the optimal goal for the treatment of depression is remission. Remission implies that the signs and symptoms of the disease are absent or virtually absent, which is typically associated with a return to the patient s previous daily functioning. Functioning in depression is a broad concept that covers different domains. There are many valida...
متن کاملPhonologically-based biomarkers for major depressive disorder
Of increasing importance in the civilian and military population is the recognition of major depressive disorder at its earliest stages and intervention before the onset of severe symptoms. Toward the goal of more effective monitoring of depression severity, we introduce vocal biomarkers that are derived automatically from phonologically-based measures of speech rate. To assess our measures, we...
متن کاملA Comparison of Emotional Schemas in Patients with Bipolar Disorders and Major Depressive Disorder in Remission and Nonclinical Population
Objective: Similarities and differences among mood disorders can help psychiatrics in their exact diagnosis and more effective treatments. Therefore, the current research sought to identify differences between patients with bipolar disorder, major depressive disorder, and nonclinical group in emotional schemas. Methods: The present research was a cross-sectional study. The research sample cons...
متن کاملNeuroimaging-based biomarkers for treatment selection in major depressive disorder
The use of neuroimaging approaches to identify likely treatment outcomes in patients with major depressive disorder is developing rapidly. Emerging work suggests that resting state pretreatment metabolic activity in the fronto-insular cortex may distinguish between patients likely to respond to psychotherapy or medication and may function as a treatment-selection biomarker. In contrast, high me...
متن کاملVortioxetine versus placebo for treatment of major depressive disorder
Introduction: Major depressive disorder is a common mental condition associated with substantial morbidity and economic burden. Approved by the FDA in September 2013 for treatment of episodes of major depressive disorder, Vortioxetine is one of the newer options available in this important area of therapeutics. Materials and methods: A comprehensive literature search (PubMed, the Cochrane libr...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Diagnostics
سال: 2021
ISSN: 2075-4418
DOI: 10.3390/diagnostics11030539